Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules

Juliana Silva Cassoli¹, Paul C Guest¹, Berend Malchow², Andrea Schmitt²,³, Peter Falkai² and Daniel Martins-de-Souza¹,³,⁴

SCHIZOPHRENIA—A RESULT OF BRAIN DISCONNECTIVITY?

One of the most recurrent findings has implicated disrupted intra- and inter-region connectivity as being the cause of many hallmark symptoms of SCZ. This is because normal brain function requires coordinated function of multiple brain regions in tasks such as perception and cognition, as well as for emotions and mood responses. Disconnectivity has been demonstrated in fronto-temporal regions, cortico-thalamo-cerebellar loops, and inter-hemispheric fibers crossing in the corpus callosum. A meta-analysis of 15 voxel-based diffusion tensor imaging studies revealed reduced fractional anisotropy as a measure of fiber density, myelination, and intra-tract coherence in left frontal and temporal lobe white matter in SCZ patients. These findings point towards disconnectivity in two distinct white matter tracts, one linking the frontal cortex, thalamus, and cingulate gyrus and the other forming a connection between the frontal cortex, insula, hippocampus, and temporal cortex. However, as chronic patients were used in these studies, it is possible that antipsychotic treatment was a confounding factor. Nevertheless, a recent meta-analysis of first episode patients with only marginal treatment also showed a reduction in fractional anisotropy, this time in the fronto-limbic circuitry involving the left inferior
Myelination of axon oligodendrocyte messenger RNA (mRNA) transcripts and proteins. This is likely to be reexpressed in a greater number of brain regions. The chronic form of the disease may show changes, which affect a greater number of brain regions.

These studies have led to the hypothesis that brain disconnection and the consequential effects on cognitive function are likely to be owing to disruption of axon myelination by oligodendrocytes. This is likely to be reflected by alterations in the patterns of oligodendrocyte messenger RNA (mRNA) transcripts and proteins. Myelination of axon fibers by oligodendrocytes is essential for rapid conduction of action potentials. This process continues through development into young adulthood and this could be important as this timing coincides with the average age of onset of SCZ.

It is well known that oligodendrocyte dysfunction can lead to disturbances in myelination and consequently to deficient propagation of nerve impulses, compromising cognitive, neural, and glial functions as observed in SCZ. This is supported by the findings of microscopic stereology and immunohistochemical studies that showed reduced oligodendrocyte density in gray matter of the prefrontal cortex, anterior thalamic nucleus, and the cormuammonis four region of the hippocampus in SCZ patients. Furthermore, electron microscopy studies have revealed dystrophic and degenerative changes of oligodendrocytes in the SCZ prefrontal cortex. However, other studies found no reductions of oligodendrocyte density in white matter, although the two-dimensional assessment of cell density used in some of these cases may have been confounded by volume differences owing to tissue shrinkage that is sometimes associated with formalin fixation. Although the primary reason for myelin and oligodendrocyte abnormalities in SCZ is not known, similar effects can be found in found in other neurological diseases with signs of inflammatory infiltration and microglial activation.

THE IMPACT OF ENVIRONMENTAL FACTORS LEADING TO OLIGODENDROCYTE DAMAGE

Along with genetic factors, an array of environmental disturbances can contribute to the development of SCZ. Epidemiological studies have shown that obstetric complications such as bleeding during pregnancy, abnormal fetal growth, premature labor, or delivery problems are associated with an increased risk of SCZ later in life. All of these scenarios can lead to the development of fetal hypoxia and inflammation, which can become pathological and have a harmful impact on tissue growth. The influence of fetal or perinatal hypoxia on SCZ-like symptoms has been shown in several reports on animal models. Likewise, the potential involvement of inflammation has been supported by a meta-analysis, which found that more than half of the SCZ candidates were associated with inflammatory or vascular function. On the other hand, there are reports showing that hypoxia at low levels is needed for blood vessel formation during embryogenesis and inflammation can protect the immature brain against viral or bacterial infection during pregnancy and may resolve itself without noxious effects. Hypoxia and inflammation induce changes in gene expression and signaling pathways associated with both physiological and pathological responses throughout the brain, although this occurs predominantly in the microglia. Hypoxia has been shown to activate microglia in the corpus callosum, thereby leading to deficits in myelination and consequently impaired axon functions. Microglia react rapidly to pathological changes in the brain by producing and releasing various pro-inflammatory cytokines and by generation of free radicals. Other studies have shown that an appropriate interaction between microglia and neurons is required to balance the processes of synaptogenesis and neuronal death during neurodevelopment and brain injury response.

Microglia are mainly activated through inflammation by damage-associated molecular pattern molecules, including ATP high-mobility group box 1 and S100 molecules, as well as pathogen-associated molecular pattern molecules, such as lipopolysaccharide. Once activated, the microglia themselves can produce both cytokines and growth factors, as well as carry out antigen presentation and phagocytosis. Thus, microglia can affect other cell types in the area such as the myelinating oligodendrocytes through regulation of inflammation and growth pathways. This is important as some studies have reported increased density of microglia in post-mortem samples from patients with SCZ and patients who had committed suicide during acute psychosis had elevated microglial cell numbers in the anterior cingulate cortex, mediodorsal thalamus, dorsolateral prefrontal cortex, and hippocampus. Also, in vivo positron emission tomography imaging analyses demonstrated microglial activation in the hippocampus of patients with SCZ using the benzodiazepine-like ligand [11C] (R)-PK11195, although treatment of patients with antipsychotics in this study may have been a confounding factor as these drugs are known to decrease cytokine levels.

Taken together, the above findings provide a plausible link between the changes identified by imaging studies regarding white matter density of brains from SCZ patients to alterations in oligodendrocyte functions, such axonal myelination. Studies have shown that cytokines released from activated microglia through hypoxia and inflammation are capable of damaging oligodendrocytes during neurodevelopment stages. For example, embryonic or neonatal animals treated with specific growth factors or cytokines such as epidermal growth factor, neuregulin 1 (NRG1), interleukin-1, or interleukin-6 exhibit disturbed oligodendrocyte function, abnormal neurotransmission, synaptic loss, and SCZ-like behavioral abnormalities after puberty. Furthermore, activation of microglia by lipopolysaccharide led to reduced survival of oligodendrocyte precursor cells in oligodendrocyte/microglia co-cultures. Thus, such disturbances could result in impaired connectivity of the developing brain up to the time of adulthood, leading to increased vulnerability of SCZ development. An elegant review has also suggested involvement of microglial or astroglial activation in white matter pathologies in SCZ. Another study showed that the anti-inflammatory agent minocycline could be used to inhibit cytokine release and increase survival and proliferation of oligodendrocyte precursor cells in an animal model of hypoxia. The same study also found that long-term impairment of white matter diffusivity in these animals was attenuated by minocycline, as shown by magnetic resonance imaging/diffusion tensor imaging analysis. Taken together, these findings provide strong evidence that neuroinflammation is associated with oligodendrocyte dysfunction in SCZ, which is likely to lead to aberrant functions in myelination and the white matter tract disturbances associated with disrupted brain connectivity and impaired cognition.

DIFFERENTIAL EXPRESSION OF MYELINATION MARKERS IN SCHIZOPHRENIA

In line with the hypothesis of oligodendrocyte dysfunction in SCZ patients and the findings described above, several molecular profiling studies of brain tissues from SCZ patients have now revealed changes in a number of proteins related to myelination. For example, a transcriptomic study carried out in 2001 found altered expression levels of myelination-related mRNAs in post-mortem dorsolateral prefrontal cortex samples, consistent with...
the oligodendrocyte hypothesis (Table 1).52 These findings have been confirmed by other researchers who also investigated myelination-related mRNA levels from post-mortem brains using microarray analyses.53–55 In addition to these findings, decreased expression in myelin- and oligodendrocyte-related mRNAs was found in other studies by quantitative PCR and in situ hybridization in post-mortem hippocampus and cortical/sub-cortical brain regions from patients with SCZ.56–59 More recently, a study employed RNA sequencing in a transcriptomic analysis of post-mortem superior temporal gyrus, which revealed significant alterations of cortical promoter usage and splicing in SCZ patients.60 Changes in claudin-11 (CLDN11) mRNA have also been detected in several studies.55,61 CLDN11 is expressed predominantly by oligodendrocytes and contributes to ~7% of the total myelin mass.56,62 Gow and collaborators reported that claudin-11 is essential for the formation of tight junctions in central nervous system (CNS) myelin through the observation that claudin-11 knockout mice exhibited neurological deficits, such as slowed CNS nerve conduction.63

In addition, proteomic studies of post-mortem brain tissues from SCZ patients have been carried out, which identified changes in proteins associated with oligodendrocytes and the process of myelination. In 2004, Prabakaran and collaborators analyzed frontal cortex samples from SCZ patients and controls and found differential expression of transferrin and 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP).54 Other studies supported these results through identification of changes in other myelination-related proteins in several different brain regions, such as myelin basic protein (MBP), myelin proteolipid protein (PLP1),67 myelin-associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG).68–71 The functions of each of these oligodendrocyte proteins are described in more detail in the following sections with a focus on their roles in myelination. It should be noted that there are some discrepancies in the literature regarding the effects on some of these molecules in post-mortem tissues, which could be due to differences in factors such as the methods applied, duration of drug treatment or post-mortem factors. However, another intriguing possibility is that the differences could relate to variations in the brain regions involved and potentially to different studies analyzing different subtypes of the disorder. For example, a recent T1 structural imaging and resting-state functional magnetic resonance imaging study by Chang and co-workers found aberrant bilateral connectivity of default mode network, inferior frontal gyrus, and cerebellum only in patients with auditory verbal hallucinations, whereas disturbances in superior temporal gyrus and precentral gyrus were specific to non-auditory verbal hallucination patients.51

CNP
CNP is an enzyme that catalyses the hydrolysis of a phosphodiester bond in 2',3'-cyclic phosphate to generate 2'-phosphate.76,77

This protein comprises ~4% of the total CNS myelin protein mass and is found in the inner and outer margins of myelin paranodal loops and oligodendrocyte cytoplasm, although it is absent from compact myelin.79 CNP undergoes post-translational modification by the addition of isoprenyl and palmitoyllipidic radicals, facilitating its binding to the plasma membranes.78,80 In addition to its phosphodiesterase activity, CNP links tubulin to cellular membranes, regulating the microtubule distribution in the cytoplasm. Consequently, it can regulate cellular morphology.81,82 Consistent with a potential role in SCZ, two genetic association studies have implicated CNP in SCZ pathogenesis.83,84 Likewise, changes in the levels of the CNP protein have been associated with behavioral deficits in mice. Edgar et al.85 that CNP knockout mice show decreased emotionality and fear compared with control mice. In addition, we found that it is a potential protein biomarker for SCZ, with altered levels found in some brain regions.74

MBP
MBP has several isoforms, although an 18.5 kDa polypeptide is the major form in adult humans and this is highly conserved in mammals. MBP isolated from brain tissues contains numerous post-translational modifications including deimination, phosphorylation, deamidation, methylation, and N-terminal acylation.86 This protein is also attached to the plasma membrane and is responsible for maintaining adhesion of the cytoplasmic surfaces of multi-lamellar compact myelin.57 In carrying out this role, MBP interacts with a variety of proteins such as calmodulin, actin, tubulin, and SH3 domain-containing proteins. Thus, it may be involved as a signaling hub in the processes of myelin development and remodeling.86 Besides the detection of altered MBP expression in SCZ using transcriptomic87 and proteomic analyses, imaging approaches have also found abnormal MBP staining in samples of SCZ brain tissues.88,89 However, another study, which used western blot analysis, found no changes in MBP protein levels in post-mortem brain tissues from patients with SCZ and other psychiatric disorders.90 Also, transcriptomic studies found no changes in MBP in post-mortem hippocampus, anterior cingulate cortex, and putamen of patients with SCZ.62 In the case of the latter, the discrepancy could be owing to differences in drug treatments and/or potential confounding factors associated with post-mortem tissues such as differences in post-mortem intervals or agonal periods. In addition, differences across studies could be due to the established fact that mRNA and protein levels are not necessarily correlated and deduction from mRNA levels alone is insufficient.91 This is why many researchers are turning to protein-based methods as these macromolecules can offer a real-time readout of physiological and biological change. Therefore, further work is essential using proteomic-based methods to establish whether MBP can be a useful biomarker of perturbed myelination in SCZ.

Table 1. Classical myelin proteins and most oligodendrocyte-related proteins differentially expressed in schizophrenia

| Proteins | UniProt ID, human | Cellular location | Gene expression reference | Proteome reference |
|----------|------------------|------------------|---------------------------|-------------------|
| 2,3-Cyclic-nucleotide 3-phosphodiesterase (CNP) | P09543.2 | Plasma membrane | 52, 56, 60–62, 64 | 16, 54, 70, 71 |
| Claudin-11 (CLDN11) | Q75508.2 | Tight junction | 55, 61–63 | — |
| Myelin basic protein (MBP) | P02686 | Plasma membrane | 55, 60, 88 | 68, 69, 71, 74 |
| Myelin proteolipid protein (PLP1) | P60201.2 | Plasma membrane | 55, 67 | 72 |
| Myelin-associated glycoprotein (MAG) | P20991.1 | Plasma membrane | 52, 53, 56, 60–62, 67 | 73 |
| Myelin oligodendrocyte glycoprotein (MOG) | Q16653.1 | Plasma membrane | 55, 56, 60, 61, 75 | 70, 71, 74 |
| Hyaluronan and proteoglycan link hyaluprotein 2 (HAPLN2) | Q9GZV7 | Secreted | — | 71 |
| Ermin (ERMN) | Q8TAM6 | Cytoskeleton | — | 71 |
| Gelsolin (GSN) | P06396 | Cytoskeleton | — | 54 |
| Transferrin (TRF) | P02787 | Cytoplasm | 52, 55, 60, 61, 64, 67, 75 | 54, 69, 106, 107 |
PLP1
PLP1 is the major protein constituent of compact myelin in the CNS comprising ~45% of the total content.92 It has fourtransmembrane-spanning domains with cytoplasmic N and Ctermini,93,94 and it is highly hydrophobic and contains severalcovalently bound fatty acid moieties essential for its function. Theextracellular loops of PLP1 include four cysteine residuesconnected through intramolecular disulfide bonds that are crucialfor protein folding, dimerization, and cellular trafficking.95 Onestudy showed that reduction of PLP1 levels greatly reducedconduction velocity of myelinated axons in mice.96 Moreover,themselves displayed anxiety-like behaviors, reduced pre-pulseinhibition, spatial learning deficits, and working memory deficits,as found in SCZ.

MAG
MAG is a cell adhesion protein found in myelin in both theCNS and peripheral nervous system (PNS) in non-compact regionsof the myelin sheath.97 This protein is extensively glycosylatedon its extracellular loops, which are composed of five tandemimmunoglobulin-like domains. The cytoplasmic domains havedifferent intracellular binding sites and properties, suggesting anintracellular signaling function and the capability of interactingwith cytoskeletal elements.98 Aiming to localize the effects of riskvariants in MAG gene on brain morphometry in SCZ patients,Felsky et al.99 showed that the temporal and parietal cortices were theareas that were most affected by MAG gene polymorphisms.

MOG
MOG is also a myelin-associated protein related to the immunoglobulin family and is comprised of 12 isoforms. As theextracellular domain of MOG is capable of undergoing dimerization, Clements et al.100 suggested that this assembly couldrepresent a homophilic adhesion complex in myelin sheaths. Otherresearchers investigated the contribution of genotypic variation of asingle-nucleotide polymorphism in MOG (rs2857766) to white matter volumes in psychotic disorders.101 They foundthat healthy G-homozygotes of the MOG single-nucleotide polymorphism had greater white matter volume in the brainstem and cerebellum compared with those with a psychotic disorder.

Other proteins
Besides the classical myelin proteins, other proteins related tooligodendrocyte function and myelination have been found to beaffected in different brain regions from SCZ patients (Table 1). Ermin is an oligodendrocyte-specific protein that appears at a latestage during myelination of mature nerves, and is localized to theouter cytoplasmic lip of the myelin sheath and paranodal loops.102 It has been proposed that this protein is involved in regulatingcytoskeletal rearrangements by binding F-actin during the latewrapping and/or compaction phases of myelination.102 Geilsolin is a Ca2+-dependent actin-binding protein that is found in manytypes of cells and produced by oligodendrocytes in the CNS. Thisprotein has also been proposed to have role in myelination it has cleavage, capping, and nucleating activities that might be important in initiating lamellipodia-like protrusivemovements of myelin along axonal segments.103 Hirakawa et al.104found that the protein hyaluronan and proteoglycan link hyaluprotein 2 (HAPLN2) could have a pivotal role in the formationof the hyaluronan-associated matrix in the CNS, which facilitatesneuronal conduction and structural stabilization by mediatingbinding of versican V2 to hyaluronic acid. Another protein that hasbeen linked to myelination functions is transferrin. This is an iron-binding glycoprotein that controls the levels of free iron in cells,tissues, and body fluids.105 In the CNS, transferrin is expressedmainly by oligodendrocytes and found to be differentiallyexpressed in many transcriptomic106 and proteomic profiling studies107 of post-mortem brain samples from SCZ patients.

NRG1/ErbB
Several isoforms of the NRG1 protein have been shown to bedifferentially expressed in post-mortem brains of SCZ patients108and mice overexpressing NRG1 types I and III have shown deficits inpre-pulse inhibition, behavioral tests and in symptoms found in SCZ.109–112 NRG1 is involved in regulation of glutamatergic receptors, oligodendrocyte proliferation, and myelination,113 and can therefore also be linked to brainconnectivity. Indeed, myelination is triggered mainly throughNRG1/ErbB signaling in oligodendrocytes. The NRG1 family is composed of four proteins belonging to the superfamily ofependimal growth factor-like ligands. Most of these are synthetized as transmembrane precursor polypeptides (pro-NRG1s) with theepidermal growth factor domain located outside the cell. Thisdomain is cleaved by proteases such as tumor necrosis factor-alpha-converting enzyme. This leads to production of matureNRG1s that are soluble, except in the case of NRG1-III. Both theN- and C-terminal regions of NRG-III are located inside the cell. Thus,NRG-III may require cell contact to exert its function.114 NRG1 proteins released from neurons bind to ErbB receptors on oligodendrocytes, which initiates several intracellular signaling cascades. The ErbB receptor family is comprised of four structurally related receptor tyrosine kinases (ErbB1–4).115 NRG1 binds to ErbB3 and ErbB4 directly. ErbB4 exists as a homodimer116,117 and ErbB1 and ErbB2 form heterodimers with ErbB4 and ErbB3, respectively. Dimerization of these proteins triggers NRG1–ErbB signaling in oligodendrocytes as summarized in Figure 1.

Regulation of the NRG1/ErbB pathway in the CNS is achievedmainly through proteolytic cleavage of membrane-bound NRGs byenzymes, such as γ-secretase,116,119 β-secretase and a disintegrinand metalloproteinase domain-containing protein 10 (ADAM10).120 Cleavage of NRG1 by ADAM10 and β-secretase releases N-terminal fragments that activate ErbB receptors. However, one study showed that ADAM10 inhibition did not affect normal myelination in a co-culture system, whereas β-secretase inhibition impaired this process.120 γ-Secretase can cleave NRG1 and the intracellular domain of the ErbB4 receptor, promoting oligodendrocyte maturation in primary cultures. However, it has been shown that cleavage is likely to blockmyelination, as inhibitors of this activity accelerate and enhance myelination.118,121

Extracellular matrix components
Several components of the extracellular matrix such as laminin,insulin-like growth factor 1 (IGF-I), and the fibroblast growth factors (FGFs) are essential in the development and function ofmyelinating cells in the CNS.122–124 Laminin receptors such as α6β1-integrin and dystroglycan in oligodendrocyte lineage cells have been shown to mediate oligodendrocyte survival, differentiation, and spatiotemporal targeting in coordination with axonal NRG1 signaling.125 Chun et al.126 showed that laminin-deficient mice developed demyelinated axons and...
reduced sheath thickness during the early stages of myelination. In this manner, extracellular laminin could contribute for creating an environment that facilitates myelin production through activation of appropriate signaling pathways.108

IGF-I is an anabolic peptide that shares homology with proinsulin.123 IGF-I is produced by all major neuronal cell types in the brain and its expression is partly regulated by pituitary growth hormone during development.127 IGF-I exerts its action by binding to the IGF-I receptor (IGF-IR), a heterotetrameric glycoprotein composed of two alpha (α) and two beta (β) subunits. The α-subunits constitute the extracellular portion of the receptor with IGF-I-binding sites, whereas the β-subunits span the membrane and initiate intracellular signal transduction via a long intracytoplasmic domain, containing intrinsic tyrosine kinase activity and other critical phosphorylation sites. Studies have shown that the overexpression of IGF-I in the mouse CNS results in increased brain growth, oligodendrocyte number, myelination, and associated myelin protein expression.128–130 This is supported by IGF-I knockout mouse studies, which showed reduced numbers of oligodendrocytes and oligodendrocyte precursor cells and decreased myelin-related proteins,131 along with decreased neuronal survival.132

FGFs are involved in many cell processes and functions, such as proliferation, differentiation, organogenesis, and myelination. FGF-1 and FGF-2 can be produced by neurons and astrocytes.133,134 and the levels of both proteins are increased during active myelination.135 Consistent with these findings, expression of FGF receptor 1 (FGFR1), FGFR2, and FGFR3 have been detected in oligodendrocytes.136,137 These receptors are composed of three immunoglobulin-like domains, a single-transmembrane helical region, and an intracellular domain with tyrosine kinase activity. A recent report showed that oligodendrocytes require FGF receptor signaling to assemble the normal number of myelin membrane wrappings around axons.138 However, this is not consistent with the findings of some previous studies, which found that FGF-2 treatment resulted in reduction of myelin formation in rats and cultured neuronal cells.139

PI3K/AKT/mTORC signaling

Regarding myelinating factors from the axolemma and extracellular matrix, the phosphatidylinositol 3 kinase serine–threonine-specific protein kinase/mammalian target of rapamycin complex (PI3K/AKT/mTORC) appears to be a point of convergence in myelination processes (Figure 2). For example, several reports have demonstrated that PI3K/AKT/mTORC signaling is activated by the neuregulins,140 integrins,141 and IGF-I.128,142 Moreover, it has been shown that the expression of constitutively active AKT1 leads to an increase of myelination in mouse oligodendrocytes.143 In terminal differentiation of oligodendrocytes, myelin protein and lipid expression can be activated by mTORC1 and mTORC2 complexes induced via PI3K/AKT/mTORC signaling.144 A study carried out by Wesseling et al.145 identified increased levels of mTOR kinase in the ketamine rat model of SCZ. Apart from effects on myelination, the mTOR kinase is also crucial for regulating expression of proteins involved in synaptic plasticity.146 In addition, mTOR signaling has been reported disrupted in SCZ patients147 and reduced levels of synaptic proteins normally induced by mTOR signaling have been reported in the prefrontal cortex of depressed patients.148 Therefore, these findings support

![Figure 1. NRG1 and ErbB signaling](image-url)

Disturbed macro-connectivity in schizophrenia

J Silva Cassoli et al

© 2015 Schizophrenia International Research Society/Nature Publishing Group npj Schizophrenia (2015) 15034
the possibility of targeting components of the mTOR signaling pathway as a potential new approach in the development of antipsychotic drugs. Other nuclear proteins involved in activation and inhibition of myelin gene transcription are also shown in Figure 2.

**FUTURE WORK: IDENTIFICATION OF NOVEL TARGETS FOR SCHIZOPHRENIA ASSOCIATED WITH OLIGODENDROCYTE AND MYELIN FUNCTION**

Considering that proteins do not work alone but rather as multi-protein complexes, pathways, or signaling cascades, further studies should be carried out to map the protein and small molecule networks associated with the oligodendrocyte-related proteins discussed in this review. This could be achieved using laboratory techniques such as tandem affinity purification, which employs a tagged protein bait for co-purification of interacting proteins in cells and mass spectrometry for identification. In addition, *in silico* methods could be applied such as Ingenuity Pathway Analysis or GeneMANIA, which can identify potential interaction partners in protein networks by superimposing laboratory data on to pre-existing networks in interaction databases. Subsequently, further mapping studies known as ‘pathway walking’ can be performed as more SCZ-related molecules are identified, thereby extending networks to include key regulatory points, which may be druggable.

As inflammation and immune activation have been implicated in the development and progression of SCZ, it follows that compounds capable of normalizing such imbalances may be helpful in treating the disease. For example, a study using a rat model of impaired...
myelin production found that oligodendrocytes recovered their function after restoration of immunglobulin Fc receptor gamma/ Fyn signaling.\textsuperscript{152} Another study showed that the antibiotic minocyclin was capable of reducing oligodendrocyte damage caused by gamma-interferon-stimulated microglia in a cell co-culture investigation\textsuperscript{153} and the same compound was used inhibit cytokine release and increase oligodendrocyte precursor cell survival in a hypoxia-based animal model, as described above.\textsuperscript{154} A recent clinical study found that adjunctive minocyclin with clozapine treatment helped to relieve impaired working memory, avolition, and depression/anxiety in chronic SCZ patients with persistent symptoms.\textsuperscript{155} On the basis of studies such as these, researchers have suggested that the best approach would be to combine the use of anti-inflammatory substances with standard antipsychotic treatment for improved treatment of those SCZ patients who also display an inflammatory phenotype.\textsuperscript{156} Furthermore, growth factors, such as IGF-I, are also under consideration as new therapeutic candidates, as the IGF pathway is known to be involved in the regulation of oligodendrocyte development and repair.\textsuperscript{157} In line with this, a recent study published in \textit{Nature} showed that IGF-I treatment restored synaptic deficits in neurons from 22q11.2 deletion patients, a syndrome characterized by an increased risk of SCZ and other psychiatric conditions.\textsuperscript{158} According to some studies, the initiation of treatment is likely to be more effective at the onset of symptoms,\textsuperscript{159} suggesting that it may be more appropriate for testing in patients with first episode psychosis and as an adjunctive treatment to antipsychotic agents, as described above for the anti-inflammatory agents.

**FINAL REMARKS**

The study of SCZ is challenging owing to its complex nature. However, breakthroughs are essential to potential shed light on new possible treatment avenues. Numerous clinical studies using imaging techniques have reported white matter changes in SCZ indicative of perturbations in connectivity within and across different brain regions. Furthermore, recent molecular studies, such as transcriptomic and proteomic profiling analyses of brain tissues and cell culture models have implicated oligodendrocyte and myelination dysfunction as significant features of the disease.\textsuperscript{160} The present review has linked imaging and molecular data on these effects in SCZ, providing an impetus for further studies in this area. It is only through an increased understanding of the disease pathways that much-needed novel drug targets can be identified.

**ACKNOWLEDGMENTS**

We dedicate our work to psychiatric patients and their families and thank them for understanding the importance of science and for having made our research possible.

**CONTRIBUTIONS**

JSC and DMS conceived the study. JSC, BM, AS, and DMS collected the data, wrote, and reviewed the manuscript. PCG and PF analyzed data and wrote the manuscript. All authors approved this version for publication.

**COMPETING INTERESTS**

AS was an honorary speaker for TAD Pharma and Roche and has been a member of advisory boards for Roche. PF has been an honorary speaker for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Essex, GE Healthcare, GlaxoSmithKline, Janssen Cilag, Lundbeck, Otsuka, Pfizer, Servier, and Takeda. During the past 5 years, but not presently, PF has been a member of the advisory boards of Janssen Cilag, AstraZeneca, Eli Lilly, and Lundbeck. The remaining authors declare no conflict of interest.

**FUNDING**

DMS and JSC are funded by FAPESP (São Paulo Research Foundation, grants 2013/08711-3, 2014/10068-4 and 2014/14881-1).

**REFERENCES**

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250: 274–285.
2. Häfner H, an der Heiden W. Schizophrenia. Blackwell Science: 2007; 101–141.
3. WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision 4th edn. WHO Library: Geneva, Switzerland, 2010.
4. Lambert M, Karov A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci 2010; 12: 393–407.
5. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318–378.
6. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421–427.
7. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. Front Neurosci 2014; 8: 19.
8. Girard TA, Christensen BK, Rizvi S. Visual-spatial episodic memory in schizophrenia: A multiple systems framework. Neuropsychology 2010; 24: 368–378.
9. Falkai P, Schmitt A, Cannon TD. Pathophysiology of schizophrenia In: Gaebel W (ed). Schizophrenia: Current Science and Clinical Practice. Wiley-Blackwell: Oxford, UK, 2011; 31–65.
10. Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry 2012; 27: 432–436.
11. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci 1995; 3: 89–97.
12. Andreasen NC. A unitary model of schizophrenia: Brelexer’s ‘fragmented phren’ as schizophrenia. Arch Gen Psychiatry 1999; 56: 781–787.
13. Crow TJ, Paez P, Chance SA. Callosal misconnectivity and the sex difference in psychosis. Int Rev Psychiatry 2007; 19: 449–457.
14. Elliotson-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 2009; 108: 3–10.
15. Yao L, Lai S, Liao Y, Du MY, Hu N, Thomas JA et al. White matter deficits in first episode schizophrenia: an activation likelihood estimation meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 43: 100–106.
16. Flyer SW, Lang DJ, Mackay AL, Goghati V, Vavassour IM, Whitlall KP et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 2003; 8: 811–820.
17. Hoistad M, Segal D, Takahashi N, Sakurai T, Buxbaum JD, Hof PR. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front Neuroanat 2009; 3: 9.
18. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008; 31: 361–370.
19. Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003; 53: 1075–1085.
20. Uranova NA, Vostrikov VM, Orlovskaya DD. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67: 269–275.
21. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94: 273–280.
22. Schmitt A, Steysskal C, Bernstein HG, Schneider-Axmann T, Parlapiani E, Schaeffer EL et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 2009; 117: 395–407.
23. Byne W, Kidkardnee S, Tatusov A, Yannioulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res 2006; 85: 245–253.
24. Vostrikov V, Orlovskaya D, Uranova N. Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World J Biol Psychiatry 2008; 9: 34–42.
25. Segal D, Schmitt C, Hof PR. Spatial distribution and density of oligodendrocytes in the cingulum bundle are unaltered in schizophrenia. Acta Neuropathol 2009; 117: 385–394.
26. Williams MR, Hampton T, Pearce RK, Hirsch SR, Ansorge O, Thom M et al. Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2013; 263: 41–52.
27. Williams RW, Rakic P. Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J Comp Neurol 1988; 278: 344–352.
28. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203–212.
Disturbed macro-connectivity in schizophrenia

J Silva Cassoli et al

29
Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. *Psychol Med* 2013; 43: 239–257.

30 Nicodemus KK, Marenco S, Batten AJ, Valkalanka R, Egan MF, Straub RE et al. Serious obstetric complications interact with hypothia-regulated/vascular-expression genes to influence schizophrenia risk. *Mol Psychiatry* 2008; 13: 873–877.

31 Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurological and psychiatric disease in children and adults. *Ann Neurol* 2012; 71: 444–457.

32 Chew LJ, Fusar-Poli P, Schmitz T. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. *Dev Neurosci* 2013; 35: 102–129.

33 Schmitz-Kastner R, van Os J, Esquivel G, Steinbusch HWM, Rutten BPF. An unusual gene expression signature of patients with schizophrenia. *Schizophr Res* 2010; 120: 150–158.

34 Kaur C, Sivakumar V, Ang LS, Sundaresan A. Hypoxic damage to the periventricular white matter in patients with schizophrenia. *Brain Dev* 2007; 29: 91–96.

35 Schmidt-Kastner R, van Os J, Esquivel G, Steinbusch HWM, Rutten BPF. Determination of activated microglia in white matter injury: relevance to schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2013; 263: 474–483.

36 Kasep S, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. *Neuropsychopharmacology* 2008; 33: 2993–3009.

37 Katsel P, Davis KL, Chi B, Wu DA, Schneider J, Haroutunian V. Gene expression abnormalities and oligodendrocyte deficits in the infratentorial cerebellum. *Schizophr Res* 2010; 120: 150–158.

38 McCullumsmith RE, Gupta D, Beneyto M, Kremen E, Haroutunian V, Davis KL et al. Gene expression alterations of Olig2 in a mouse model of schizophrenia. *J Neurosci* 2011; 31: 13444–13453.

39 Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry* 2004; 9: 684–69743.

40 Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet* 2003; 362: 798–805.

41 Banks K, Dracheva S, Byne W. Subcortical oligodendrocyte-astrocyte associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. *Schizophr Res* 2009; 112: 54–64.

42 Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. *Neuropsychopharmacology* 2008; 33: 2993–3009.

43 Kaur C, Sivakumar V, Ang LS, Sundaresan A. Hypoxic damage to the periventricular white matter in patients with schizophrenia. *Brain Dev* 2007; 29: 91–96.

44 Steinbichler M, Reiderer P, Czlonkowska A, Heinz A. Abnormal expression of synaptic genes in the cerebellum of patients with schizophrenia and bipolar disorder. *Biol Psychiatry* 2010; 67: 1029–1037.

45 Kasep S, Davis KL, Chi B, Wu DA, Schneider J, Haroutunian V. Gene expression abnormalities and oligodendrocyte deficits in the infratentorial cerebellum. *Schizophr Res* 2010; 120: 150–158.

46 Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with neuron function. *Mol Psychiatry* 2009; 14: 1083–1094.

47 Wujii C, Wang X, Beveridge NJ, Tooney PA, Scott RJ, Cair VJ et al. Transcriptome sequencing revealed significant alteration of cortical promoter usage and splicing in schizophrenia. *PloS One* 2012; 7: e36351.

48 Katsel P, Davis KL, Haroutunian V. Variants in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. *Schizophr Res* 2005; 79: 157–173.

49 Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex in schizophrenia. *Mol Psychiatry* 2012; 17: 1194–1205.

50 Najjar S, Pearlman DM. Neuroinflammation in schizophrenia. *Acta Neuropathol* 2010; 120: 589–600.

51 Schmidt-Kastner R, van Os J, Esquivel G, Steinbusch HWM, Rutten BPF. An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. *Mol Psychiatry* 2012; 17: 1194–1205.

52 Kaur C, Sivakumar V, Ang LS, Sundaresan A. Hypoxic damage to the periventricular white matter in neonatal brain: role of vascular endothelial growth factor, nitric oxide and excitotoxicity. *J Neurochem* 2006; 98: 1200–1206.

53 Hanisch UK. Microglia as a source and target of cytokines. *GLI* 2002; 40: 140–155.

54 Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M et al. Neuro-inflammation in schizophrenia especially focused on the role of microglia. *Prog Neurophysiopathol Biol* 2013; 42: 115–121.

55 Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. *Physiol Rev* 2011; 91: 461–553.

56 Wierzb-Kobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasiecznik E. Quantitative analysis of activated microglia, ramified and damaged of processes in the frontal and temporal lobes of chronic schizophrenics. *Folia Neuropathol* 2005; 43: 81–89.

57 Bussier SE, Busse M, Schütz K, Bielaus H, Gos T, Brisch R et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? *Brain Behav Immun* 2012; 26: 1273–1279.

58 Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. *Acta Neuropathol* 2006; 112: 305–316.

59 Schmitz-Kastner R, Bielaus H, Brisch R, Danos P, Ullrich O, Mawrin C et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. *J Psychiatr Res* 2008; 42: 151–157.

60 Schneider TP, Dworzok AJ. Searching for neuropathology: gliosis in schizophrenia. *Biolog Psychiatry* 2011; 69: 134–139.

61 Doorduijn J, de Vries EW, Willemsen AT, de Groot JC, Diercks RA, Klein HC. Neuro-inflammation in schizophrenia-related psychosis: a PET study. *J Nucl Med* 2009; 50: 1801–1807.

62 Kato T, Monji A, Hashioka S, Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. *Schizophr Res* 2007; 92: 108–115.

63 Wang HLab E, Somaya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. *Psychiatry Clin Neurosci* 2010; 64: 217–230.

64 Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. *Schizophr Res* 2015; 161: 102–112.

65 Schmitz T, Krabbe G, Weikert G, Scheuer T, Mathieu F, Wang Y et al. Minocycline protects the immature white matter against hypoxia. *Eur Neurol* 2014; 254: 153–165.

66 Hakay Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. *Proc Natl Acad Sci USA* 2001; 98: 4746–4751.

67 Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. *J Neurosci* 2004; 77: 858–866.

68 Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry* 2004; 9: 684–69743.

69 Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet* 2003; 362: 798–805.
100 Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG  © 2015 Schizophrenia International Research Society/Nature Publishing Group npj Schizophrenia (2015) 15034

102 Brockschnieder D, Sabanay H, Riemich D, Peles E. Ermin, a myelinating anchor for tubulin. Proc Natl Acad Sci USA 2002; 99: 1807–1812.

103 Vouyiouklis DA, Brophy PJ. A novel gelsolin isoform expressed by oligodendrocytes to bind to membranes. J Neurosci Res 1991; 30: 540–544.

104 Sazdaan KN, Tchrakian-Abdollahi N, Kianikani P, Harmony B, Doroudchi S, Setayesh M. The effect of zinc on the level of 2',3'-cyclic nucleotide 3'-phosphodiesterase mRNA in rat brain in normal and Alzheimer's disease mice. J Enzyme Inhib 2009; 24: 114–118.

105 Crichton RR, Charloteaux-Wauters M. Iron transport and storage. J Biol Chem 1999; 274: 34155–34162.

106 Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior chicken retina. J Cell Biol 2003; 160: 649–662.

107 Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski N et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 2008; 28: 6872–6883.

108 Deakin IH, Law AJ, Oliver PL, Schwab MH, Nave KA, Harrison PJ et al. Behavioural characterisation of neuregulin-1 type 1 overexpressing transgenic mice. Neureport 2009; 20: 1523–1528.

109 Drummond PK, Catlett M, Blumberg ME, Kiyatkin A, Cheung K, Standaert DG et al. Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity. Cell Rep 2014; 8: 1130–1145.

110 Schmitt A, Koschel J, Zink M, Bauer M, Sommer C, Frank J et al. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010; 260: 101–111.

111 Deakin IH, Law AJ, Oliver PL, Schwab MH, Nave KA, Harrison PJ et al. Behavioural characterisation of neuregulin-1 type 1 overexpressing transgenic mice. Neureport 2009; 20: 1523–1528.

112 Aronson KR, Nave KA. The cellular biology of oligodendrocytes in the mammalian central nervous system. Physiol Rev 2001; 81: 871–927.

113 Schmitt A, Koschel J, Zink M, Bauer M, Sommer C, Frank J et al. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010; 260: 101–111.

114 Meyer D, Yamaai T, Garratt A, Riethermacher-Sonnenberg E, Kane D, Thelli LE et al. Isoform-specific expression and function of neuregulin. Development 1997; 124: 3575–3586.

115 Birchmeier C, Erb B receptors and the development of the nervous system. J Cell Res 2009; 315: 611–618.

116 Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14–30.

117 Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437–452.

118 Lai C, Feng L. Implication of gamma-secretase in neuregulin-induced maturation of oligodendrocytes. Biochem Biophys Res Commun 2004; 314: 535–542.

119 Bao J, Wolpowitz D, Role LW, Talghade MA. Back signaling by the Nrg-1 receptor promotes target-dependent survival. J Cell Biol 2009; 185: 23967–23974.

120 Chun SJ, Rasband MN, Sidman RL, Habib AA, Vartanian T. Integrin-linked kinase: a potential therapeutic target for schizophrenia. Mol Psychiatry 2005; 10: 841–853.

121 Lai C, Feng L. Implication of gamma-secretase in neuregulin-induced maturation of oligodendrocytes. Biochem Biophys Res Commun 2004; 314: 535–542.

122 Colognato H, Tzvetanova ID. Glia unglued: how signals from the extracellular matrix regulate myelin thickness and function. Trends Cell Biol 2005; 15: 11849–11853.

123 O’Kusky J, Ye P. Neurodevelopmental effects of insulin-like growth factor I (IGF-I) gene expression in brain of transgenic mice. J Neurosci 2008; 28: 1145–1155.

124 Furusho M, Dupree JL, Nave KA, Bansal R. Fibroblast growth factor receptor 2 signalling in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J Cell Biol 2005; 167: 661–673.

125 Peirce TR, Bray NJ, Williams NM, Norton N, Moskvina V, Preece A et al. Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 2006; 63: 18–24.

126 Chun SJ, Rasband MN, Sidman RL, Habib AA, Vartanian T. Integrin-linked kinase: a potential therapeutic target for schizophrenia. Mol Psychiatry 2005; 10: 841–853.

127 Glygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720–1730.

128 Carson MJ, Behringer RR, Brinster RL, McMorris FA. Insulin-like growth factor I gene expression in brain of transgenic mice. J Neurosci 1992; 12: 276–287.

129 Koo JD, Zhang M, Trebak-Muff I. Pre-natal glial injury disrupts neural outgrowth and alters development of the visual system. J Neurosci 2003; 23: 225–236.

130 Trapp BD, Quares RH. Presence of the myelin-associated glycoprotein correlates with alterations in the periodicity of peripheral myelin. J Cell Biol 1982; 92: 877–882.

131 Kursula P, Lehto VP, Heape AM. The small myelin-associated glycoprotein binds to tubulin and microtubules. Brain Res Mol Brain Res 2001; 87: 22–30.

132 Felsky D, Voinoskos AN, Lerch JP, Nazien A, Shalakh SA, Raji TK et al. Myelin-associated glycoprotein and brain morphology in schizophrenia. Psychiatr Res 2012; 3: 40.

133 Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG et al. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci USA 2003; 100: 11059–11064.

134 Cannon DM, Wolske M, Dempster E, Collier DA, Marshall N, Bramon E et al. The association of white matter volume in psychotic disorders with genotypic variation in NRG1, MOG and CNP: a voxel-based analysis in affected individuals and their unaffected relatives. Trans Psychiatry 2012; 2: e167.

135 Brockmiedere D, Sabany H, Riemich D, Peles E. Ermin, a myelinating oligodendrocyte-specific protein that regulates cell morphology. J Neurosci 2006; 26: 757–762.

136 Vouyioukis DA, Brophy PJ. A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system. J Neurochem 1997; 69: 995–1005.

137 Hirakawa S, Oohashi T, Su WD, Yoshikoa H, Murakami T, Arata J et al. The brain link protein-1 (BRAL) gene maps to 1q21.3-1q22 and is transcribed in the rat brain. Brain Res Mol Brain Res 2000; 276: 982–989.

138 Crichton RR, Charlotteaux-Wauters M. Iron transport and storage. Eur J Biochem 1987; 164: 485–506.

139 Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 2006; 11: 459–470, 23.

140 Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102–1117.

141 Ahrendt JS, Macklin W. Signaling mechanisms regulating myelination in the central nervous system. Neurosci Bull 2013; 29: 199–215.

142 Schmitt A, Parlapani E, Gruber O, Wobrock T, Falkai P. Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 5): 35–39.

143 Beasley CL, Honer WG, Bergmann K, Falkai P, Lutjohann D, Bayer TA. Reductions in the expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase and its mRNA in the rat central nervous system is fatty-acylated by thioester linkage. J Biol Chem 1998; 273: 7576–7583.

144 Beasley CL, Honer WG, Bergmann K, Falkai P, Lutjohann D, Bayer TA. Reductions in the expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase and its mRNA in the rat central nervous system is fatty-acylated by thioester linkage. J Biol Chem 1998; 273: 7576–7583.
Disturbed macro-connectivity in schizophrenia
J Silva Cassoli et al

10. Goddard DR, Berry M, Butt AM. In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-1 on oligodendrocyte development and myelination in the central nervous system. J Neurosci Res 1999; 57: 74–85.

13. Ye P, Li L, Richards RG, DeAugustine RP, D’Ercole AJ. Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 2002; 22: 6041–6051.

15. Zeger M, Pupken G, Zhang J, Xuan S, Lu QR, Schwab MH et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007; 55: 400–411.

16. Riva MA, Moccetti I. Developmental expression of the basic fibroblast growth factor gene in rat brain. Brain Res Dev Brain Res 1991; 62: 45–50.

17. Matsuyama A, Iwata H, Okumura N, Yoshida S, Imaizumi K, Lee Y et al. Localization of basic fibroblast growth factor-like immunoreactivity in the rat brain. Brain Res 1992; 587: 49–65.

18. Ratzka A, Baron O, Grothe C. FGF-2 deficiency does not influence FGF ligand and receptor expression during development of the neuroepithelial system. PLoS One 2011; 6: e23564.

19. Fortin D, Rom E, Sun H, Yayon A, Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005; 25: 7470–7479.

20. Furusho M, Kaga Y, Ishii A, Hebert JM, Bansal R. Fibroblast growth factor signaling is required for the generation of oligodendrocyte progenitors from the embryonic forebrain. J Neurosci 2011; 31: 5055–5066.

21. Baron W, de Jonge JC, de Vries H, Hoekstra D. Perturbation of myelination by activation of distinct signaling pathways: an in vitro study in a myelinating culture derived from fetal rat brain. J Neurosci Res 2000; 59: 74–85.

22. Wang Z, Colognato H, Ffrench-Constant C. Contrasting effects of mitogenic growth factors on myelination in neuron-oligodendrocyte co-cultures. Glia 2007; 55: 537–545.

23. Tavgeggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 2005; 47: 681–694.

24. Barros CS, Nguyen T, Spencer KS, Nishiya A, Colognato H, Muller U. Beta1 integrins are required for normal CNS myelination and promote AKT-dependent myelin outgrowth. Development 2009; 136: 2717–2724.

25. Ness JK, Mitchell NE, Wood TL. IGF-1 and NT-3 signaling pathways in developing oligodendrocytes: differential regulation and activation of receptors and the downstream effector Akt. Dev Neurosci 2002; 24: 437–445.

26. Flores AI, Narayanian SP, Morse EN, Shick HE, Yin X, Kidd G et al. Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci 2008; 28: 7174–7183.

27. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW et al. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 2009; 29: 6367–6378.

28. Wesseling H, Rahmouve H, Tricklebank M, Guest PC, Bahn S. A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain. J Proteome Res 2015; 14: 411–421.